NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
Neuraxis, Inc. (NRXS)
Company Research
Source: GlobeNewswire
CARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it received a new 510(k) clearance for IB-Stim™ Nonimplanted Nerve Stimulator for functional abdominal pain relief. The new indication expands IB-Stim’s addressable market and overall devices per patient. NeurAxis leveraged its robust published data to receive this new indication. “We are excited to receive this new 510(k) clearance for IB-Stim, which expands the IB-Stim addressable market by roughly 75%,” said Brian Carrico, President and Chief Executive Officer of NeurAxis. “Furthermore, we expect devices per patient to increase, as this new FDA clearance states on label use of four devices per patient. All of this has been achieved due to the strong body of published research, which has resulted in the i
Show less
Read more
Impact Snapshot
Event Time:
NRXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXS alerts
High impacting Neuraxis, Inc. news events
Weekly update
A roundup of the hottest topics
NRXS
News
- NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation [Yahoo! Finance]Yahoo! Finance
- NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic ConstipationGlobeNewswire
- NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage [Yahoo! Finance]Yahoo! Finance
- NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues [Yahoo! Finance]Yahoo! Finance
- NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in RevenuesGlobeNewswire
NRXS
Sec Filings
- 12/13/24 - Form S-3
- 12/2/24 - Form SC
- 12/2/24 - Form SC
- NRXS's page on the SEC website